215 related articles for article (PubMed ID: 15466821)
21. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II.
Ferguson PJ; Currie C; Vincent MD
Drug Metab Dispos; 1999 Dec; 27(12):1399-405. PubMed ID: 10570020
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
[TBL] [Abstract][Full Text] [Related]
23. The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line.
Johnston PG; Geoffrey F; Drake J; Voeller D; Grem JL; Allegra CJ
Eur J Cancer; 1996 Nov; 32A(12):2148-54. PubMed ID: 9014759
[TBL] [Abstract][Full Text] [Related]
24. Inhibition by 5-fluorouracil of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human squamous carcinoma cell line.
Esaki T; Nakano S; Tatsumoto T; Kuroki-Migita M; Mitsugi K; Nakamura M; Niho Y
Cancer Res; 1992 Dec; 52(23):6501-6. PubMed ID: 1423296
[TBL] [Abstract][Full Text] [Related]
25. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
26. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
[TBL] [Abstract][Full Text] [Related]
27. Comparisons of carboplatin and cisplatin as potentiators of 5-fluorouracil and radiotherapy in the mouse L1210 leukaemia model.
Dionet CA; Rapp M; Tchirkov A
Anticancer Res; 2002; 22(2A):721-5. PubMed ID: 12014642
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo chemosensitivity of head and neck carcinoma to cytostatic drug combinations.
Dollner R; Granzow C; Neudert M; Dietz A
Anticancer Res; 2006; 26(2B):1651-5. PubMed ID: 16619587
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy of the squamous cell lung cancer LC-12 with 5-fluorouracil, cisplatin, carboplatin or iproplatin combinations.
Tapazoglou E; Polin L; Corbett TH; al-Sarraf M
Invest New Drugs; 1988 Dec; 6(4):259-64. PubMed ID: 3068184
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
32. Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice.
Papadopoulou MV; Ji M; Bloomer WD
Cancer Chemother Pharmacol; 2001 Aug; 48(2):160-8. PubMed ID: 11561782
[TBL] [Abstract][Full Text] [Related]
33. Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies.
Hung CC; Chien CY; Chu PY; Wu YJ; Lin CS; Huang CJ; Chan LP; Wang YY; Yuan SF; Hour TC; Chen JY
Head Neck; 2017 Aug; 39(8):1621-1630. PubMed ID: 28498554
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
35. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bourhis J; Rivera F; Mesia R; Awada A; Geoffrois L; Borel C; Humblet Y; Lopez-Pousa A; Hitt R; Vega Villegas ME; Duck L; Rosine D; Amellal N; Schueler A; Harstrick A
J Clin Oncol; 2006 Jun; 24(18):2866-72. PubMed ID: 16717293
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Brickelmaier M; Carmillo A; Goelz S; Barsoum J; Qin XQ
J Interferon Cytokine Res; 2002 Aug; 22(8):873-80. PubMed ID: 12396726
[TBL] [Abstract][Full Text] [Related]
37. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
[TBL] [Abstract][Full Text] [Related]
38. Broccoli extract improves chemotherapeutic drug efficacy against head-neck squamous cell carcinomas.
Elkashty OA; Ashry R; Elghanam GA; Pham HM; Su X; Stegen C; Tran SD
Med Oncol; 2018 Aug; 35(9):124. PubMed ID: 30078069
[TBL] [Abstract][Full Text] [Related]
39. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
40. Platinum compounds in the treatment of advanced breast cancer.
MartÃn M
Clin Breast Cancer; 2001 Oct; 2(3):190-208; discussion 209. PubMed ID: 11899413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
